October 24, 2013

SeeThruEquity, LLC Initiates Coverage on Pressure BioSciences, Inc.

SOUTH EASTON, Mass., Oct. 24, 2013 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that SeeThruEquity, LLC, an independent investment research and corporate access firm, has initiated equity research coverage on the Company. The research report is available for viewing and downloading at www.seethruequity.com.

Any opinions, judgments, estimates, or forecasts regarding the Company's historical or predicted performance or operations made by SeeThruEquity, LLC are theirs alone and do not represent opinions, judgments, estimates, or forecasts of the Company or its management. The Company does not by its reference to the research report prepared by SeeThruEquity, LLC imply its endorsement or adoption of or concurrence with such information, conclusions, or recommendations.

The investment opinions expressed are solely those of SeeThruEquity, LLC. SeeThruEquity, LLC has not been compensated for the preparation of the report on the Company by any third party or the Company.

About SeeThruEquity LLC:

SeeThruEquity, LLC is an investment research and corporate access firm that produces high quality research reports on smallcap and microcap companies with less than $1 billion in market capitalization. **The research is unbiased and not paid-for research** These companies have typically been underserved by the traditional Wall Street analyst establishment. We are unfettered by any ties to investment banking or trading, and distribute our high impact research as an approved contributor on Thomson Reuters One (First Call), CapitalIQ, FactSet, Zacks and StockTwits, as well as to our own audience of investors from our corporate website. We also contribute our financial estimates on companies in our research coverage universe to Thomson Estimates (commonly referred to as consensus or consensus estimates on the Street).

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and

counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts:
Richard T. Schumacher, President and CEO (508) 230-1828 (T)
Richard P. Thomley, Acting CFO

SOURCE Pressure BioSciences, Inc.